David P. Astling
YOU?
Author Swipe
View article: Olduvai domain expression downregulates mitochondrial pathways: implications for human brain evolution and neoteny
Olduvai domain expression downregulates mitochondrial pathways: implications for human brain evolution and neoteny Open
Encoded by the NBPF gene family, Olduvai (formerly DUF1220) protein domains have undergone the largest human lineage-specific copy number expansion of any coding region in the genome. Olduvai copy number shows a linear relationship with se…
View article: Crossing the Halfway Point: Aptamer-Based, Highly Multiplexed Assay for the Assessment of the Proteome
Crossing the Halfway Point: Aptamer-Based, Highly Multiplexed Assay for the Assessment of the Proteome Open
Measuring responses in the proteome to various perturbations improves our understanding of biological systems. The value of information gained from such studies is directly proportional to the number of proteins measured. To overcome techn…
View article: Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission
Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission Open
OBJECTIVE To determine the extent to which changes in plasma proteins, previously predictive of cardiometabolic outcomes, predict changes in two diabetes remission trials. RESEARCH DESIGN AND METHODS We applied SomaSignal predictive tests …
View article: Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission
Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission Open
Objective: To determine to what extent changes in plasma proteins, previously predictive of cardiometabolic outcomes, predict changes in two diabetes remission trials.Research Design and Methods: SomaSignal® predictive tests (each derived …
View article: Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission
Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission Open
Objective: To determine to what extent changes in plasma proteins, previously predictive of cardiometabolic outcomes, predict changes in two diabetes remission trials.Research Design and Methods: SomaSignal® predictive tests (each derived …
View article: Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in squamous…
View article: Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 956K, Supplementary Figure 1. A, Cellular viability of 6 sensitive and 5 resistant cell lines at 1.0μM rigosertib treatment as measured by SRB assay; Supplementary Figure 2. Proliferation of 2 rigosertib-sensitive (584 and HN11)…
View article: Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 64K
View article: Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in squamous…
View article: Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 64K
View article: Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 112K, Supplementary Table 1. Cell Line GSEA; Supplementary Table 2. Cell Line Mutation Status; Supplementary Table 3. PIK3CA Amplification in the Orthotopically Implanted Cell Lines; Supplementary 4 PIK3CA Amplification in the D…
View article: Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 112K, Supplementary Table 1. Cell Line GSEA; Supplementary Table 2. Cell Line Mutation Status; Supplementary Table 3. PIK3CA Amplification in the Orthotopically Implanted Cell Lines; Supplementary 4 PIK3CA Amplification in the D…
View article: Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 956K, Supplementary Figure 1. A, Cellular viability of 6 sensitive and 5 resistant cell lines at 1.0μM rigosertib treatment as measured by SRB assay; Supplementary Figure 2. Proliferation of 2 rigosertib-sensitive (584 and HN11)…
View article: Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies Open
Supplemental Figure S1: Supplemental Figure 1 shows the pharmacokinetic plasma concentration curve following a single dose of oral rigosertib, revealing dose-dependent pharmacokinetics; Supplemental Table S1: This file provides individual …
View article: Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies Open
Supplemental Figure S1: Supplemental Figure 1 shows the pharmacokinetic plasma concentration curve following a single dose of oral rigosertib, revealing dose-dependent pharmacokinetics; Supplemental Table S1: This file provides individual …
View article: Data from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Data from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies Open
Purpose: To determine the pharmacokinetics (PK), maximum tolerated dose (MTD), safety, and antitumor activity of an oral formulation of rigosertib, a dual phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (Plk1) pathway inhibitor, in…
View article: Data from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Data from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies Open
Purpose: To determine the pharmacokinetics (PK), maximum tolerated dose (MTD), safety, and antitumor activity of an oral formulation of rigosertib, a dual phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (Plk1) pathway inhibitor, in…
View article: Data from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer
Data from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer Open
Obese postmenopausal women have increased risk of breast cancers with poorer clinical outcomes than their lean counterparts. However, the mechanisms underlying these associations are poorly understood. Rodent model studies have recently id…
View article: Supplementary Methods, Tables 1-4, Figure 1 from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer
Supplementary Methods, Tables 1-4, Figure 1 from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer Open
PDF file - 219K, Supplemental Methods, including: (1)Detailed description of obesity and postmenopausal breast cancer model (2)Criteria for removal of animals from the study (3)Western blotting methods (4)Detailed methods for adipocyte cel…
View article: Supplementary Methods, Tables 1-4, Figure 1 from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer
Supplementary Methods, Tables 1-4, Figure 1 from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer Open
PDF file - 219K, Supplemental Methods, including: (1)Detailed description of obesity and postmenopausal breast cancer model (2)Criteria for removal of animals from the study (3)Western blotting methods (4)Detailed methods for adipocyte cel…
View article: Data from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer
Data from Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer Open
Obese postmenopausal women have increased risk of breast cancers with poorer clinical outcomes than their lean counterparts. However, the mechanisms underlying these associations are poorly understood. Rodent model studies have recently id…
View article: Additional file 6 of Genome-wide copy number variations in a large cohort of bantu African children
Additional file 6 of Genome-wide copy number variations in a large cohort of bantu African children Open
Additional file 6. CNV blocks overlapped with DDG2P genes. Description: The list of Bantu CNV blocks overlapped with DDG2P genes.
View article: Additional file 5 of Genome-wide copy number variations in a large cohort of bantu African children
Additional file 5 of Genome-wide copy number variations in a large cohort of bantu African children Open
Additional file 5. The list of DDG2P genes used in our analysis. Description: The list of DDG2P genes used in our analysis to detect genes overlapping with Bantu CNV blocks.
View article: Additional file 3 of Genome-wide copy number variations in a large cohort of bantu African children
Additional file 3 of Genome-wide copy number variations in a large cohort of bantu African children Open
Additional file 3. The list of CNVRs. Description: The list of CNVRs identified in our study.
View article: Additional file 1 of Genome-wide copy number variations in a large cohort of bantu African children
Additional file 1 of Genome-wide copy number variations in a large cohort of bantu African children Open
Additional file 1. Bantu Samples Demographic Info. Description: The list of Bantu samples with demographic information.
View article: Additional file 8 of Genome-wide copy number variations in a large cohort of bantu African children
Additional file 8 of Genome-wide copy number variations in a large cohort of bantu African children Open
Additional file 8. The list of CNVs associated with DECIPHER Syndromes used in our analysis: Description: The list of DECIPHER CNV syndromes used in our study.
View article: Additional file 2 of Genome-wide copy number variations in a large cohort of bantu African children
Additional file 2 of Genome-wide copy number variations in a large cohort of bantu African children Open
Additional file 2. The list of CNVs. Description: The list of CNVs detected in our study.